MetaVia (MTVA) EPS (Basic) Growth (5y) (2020 - 2026)
MetaVia (MTVA) EPS (Basic) Growth (5y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.38% |
| Dec 31, 2025 | 79.71% |
| Sep 30, 2025 | 68.50% |
| Jun 30, 2025 | 62.47% |
| Mar 31, 2025 | 65.43% |
| Dec 31, 2024 | 74.45% |
| Sep 30, 2024 | 79.26% |
| Jun 30, 2024 | 72.73% |
| Mar 31, 2024 | 75.83% |
| Dec 31, 2023 | 14.88% |
| Sep 30, 2023 | 80.34% |
| Jun 30, 2023 | 86.11% |
| Mar 31, 2023 | 82.87% |
| Dec 31, 2022 | 66.54% |
| Sep 30, 2022 | 64.39% |
| Jun 30, 2022 | 65.32% |
| Mar 31, 2022 | 64.72% |
| Dec 31, 2021 | 63.62% |
| Sep 30, 2021 | 59.41% |
| Jun 30, 2021 | 55.92% |